[go: up one dir, main page]

BR0017120A - Composição farmacêutica - Google Patents

Composição farmacêutica

Info

Publication number
BR0017120A
BR0017120A BR0017120-4A BR0017120A BR0017120A BR 0017120 A BR0017120 A BR 0017120A BR 0017120 A BR0017120 A BR 0017120A BR 0017120 A BR0017120 A BR 0017120A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pyrimidinyl
phenylethenenesulfonamide
methoxyphenoxy
methoxy
Prior art date
Application number
BR0017120-4A
Other languages
English (en)
Inventor
Hironori Yuyama
Akira Fujimori
Masanao Sanagi
Hironori Harada
Akiko Koakutsu
Mikiko Mori
Nobuyuki Yamamoto
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of BR0017120A publication Critical patent/BR0017120A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA". Composição farmacêutica para tratamento terapêutico de câncer de próstata, a composição farmacêutica contendo N-[6-metóxi-5-(2-metoxifenóxi)-2-(2-pirimidinil)-4-pirimidinil]-2-fenileten ossulfonamida ou um sal farmaceuticamente aceitável da mesma como o componente eficaz.
BR0017120-4A 2000-02-16 2000-10-27 Composição farmacêutica BR0017120A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000037313 2000-02-16
JP2000037314 2000-02-16
PCT/JP2000/007573 WO2001060370A1 (fr) 2000-02-16 2000-10-27 Remedes contre les maladies induites par l'endotheline

Publications (1)

Publication Number Publication Date
BR0017120A true BR0017120A (pt) 2003-01-14

Family

ID=26585418

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0017120-4A BR0017120A (pt) 2000-02-16 2000-10-27 Composição farmacêutica

Country Status (15)

Country Link
US (1) US6774131B1 (pt)
EP (1) EP1256344B1 (pt)
JP (2) JP3832229B2 (pt)
KR (1) KR20020075797A (pt)
CN (1) CN1434715A (pt)
AR (1) AR031679A1 (pt)
AT (1) ATE348617T1 (pt)
AU (1) AU2000279614A1 (pt)
BR (1) BR0017120A (pt)
CA (1) CA2395711A1 (pt)
DE (1) DE60032517T2 (pt)
ES (1) ES2277856T3 (pt)
HU (1) HUP0204139A3 (pt)
RU (1) RU2002124599A (pt)
WO (1) WO2001060370A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
EP2114418A4 (en) * 2007-02-09 2013-01-09 Poniard Pharmaceuticals Inc ORAL DOSAGE FORM WITH STABILIZED PICOPLATIN
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
EP2244714A4 (en) * 2008-02-08 2012-06-06 Poniard Pharmaceuticals Inc USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
EP2294056A1 (en) * 2008-05-23 2011-03-16 Synthon B.V. Bosentan salts
CN104995313A (zh) 2012-10-12 2015-10-21 生物运动有限公司 使用c-maf的前列腺癌转移的诊断、预后和治疗的方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882719B1 (en) * 1995-12-20 2001-05-16 Yamanouchi Pharmaceutical Co. Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
US6030975A (en) 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
US6673832B1 (en) * 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain

Also Published As

Publication number Publication date
DE60032517T2 (de) 2007-10-04
HUP0204139A3 (en) 2003-07-28
CA2395711A1 (en) 2002-07-18
JP3832229B2 (ja) 2006-10-11
EP1256344B1 (en) 2006-12-20
JP2006176542A (ja) 2006-07-06
DE60032517D1 (de) 2007-02-01
KR20020075797A (ko) 2002-10-05
HUP0204139A2 (en) 2003-05-28
RU2002124599A (ru) 2004-03-10
CN1434715A (zh) 2003-08-06
ATE348617T1 (de) 2007-01-15
AU2000279614A1 (en) 2001-08-27
EP1256344A4 (en) 2004-12-29
WO2001060370A1 (fr) 2001-08-23
AR031679A1 (es) 2003-10-01
US6774131B1 (en) 2004-08-10
EP1256344A1 (en) 2002-11-13
JP2001302514A (ja) 2001-10-31
ES2277856T3 (es) 2007-08-01

Similar Documents

Publication Publication Date Title
BR0017120A (pt) Composição farmacêutica
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
BR0109703A (pt) Derivados de piperazina
LU92642I2 (fr) Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid)
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
EA200500853A1 (ru) 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
MXPA04001114A (es) Derivados de aminoindazol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
CR10114A (es) Composiciones farmacéuticas que comprenden inhibidoras de la hmg coa reductasa (divisional del exp. 6687)
GEP20053675B (en) Pyridazinone Aldose Reductase Inhibitors
PT1119543E (pt) N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
AR031766A1 (es) Terapia
BR0113590A (pt) 7-oxo-piridopirimidinas
TR200201245T2 (tr) Kanser tedavisi için onkolitik kombinasyonlar.
NO20023486L (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
EP1453507A4 (en) SOLUBILIZED TOPOISOMERASE GIFT MEDIUM
BR0308911A (pt) Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto
BRPI0414527A (pt) tratamento de tumores estromáticos gastrointestinais com imatinib e midostaurina
RU2003133136A (ru) Новое применение производных арилэтенсульфонамида
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.